BMS 753

CAS No. 215307-86-1

BMS 753( —— )

Catalog No. M33783 CAS No. 215307-86-1

BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 55 Get Quote
10MG 92 Get Quote
25MG 205 Get Quote
50MG 329 Get Quote
100MG 447 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BMS 753
  • Note
    Research use only, not for human use.
  • Brief Description
    BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
  • Description
    BMS 753 is an isotype-selective retinoic acid receptor α (RARα) agonist, with a Ki of 2 nM.
  • In Vitro
    BMS 753 results in low levels of RARβ transcripts in WT cells, RARγ-/-, but not activates in RARa-/- cells.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Retinoid Receptor
  • Recptor
    Retinoid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    215307-86-1
  • Formula Weight
    351.4
  • Molecular Formula
    C21H21NO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (142.29 mM; Ultrasonic )
  • SMILES
    CC1(C)C(=O)C(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. M Géhin, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29.?
molnova catalog
related products
  • BMS 195614

    BMS 195614 (BMS614) is a selective RARα antagonist. BMS 195614 can bind to the RARα subunit.

  • Bexarotene

    Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.

  • ER 50891

    ER-50891 is a potent retinoic acid receptor alpha (RARα) antagonist. er-50891 reduces the inhibitory effect of allosteric retinoic acid and restores osteoblast differentiation induced by bone morphogenetic protein 2.